Keros Therapeutics(US:KROS) Globenewswire·2026-03-09 12:00Core Viewpoint - Keros Therapeutics has entered into a collaboration with Massachusetts General Hospital to design a Phase 2 clinical trial for rinvatercept in patients with amyotrophic lateral sclerosis (ALS) as part of the Healey ALS MyMatch program [1][2][3] Group 1: Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins [1][7] - The company's lead product candidate, rinvatercept, is being developed for the treatment of both Duchenne muscular dystrophy and ALS [1][8] Group 2: Clinical Trial and Collaboration - The collaboration with the Healey & AMG Center aims to accelerate the development of new therapies for ALS through biomarker-driven personalized trial approaches [2][4] - The ALS MyMatch program integrates genetic and biofluid markers to match ALS patients with experimental therapies based on their disease markers [2][4] - Rinvatercept is believed to have the potential to preserve muscle strength and improve quality of life for ALS patients, according to Keros' CEO [3][6] Group 3: Research and Development - Rinvatercept functions as a ligand trap to inhibit the biological effects of myostatin and activin A, which negatively regulate muscle and bone mass [6] - The Healey ALS MyMatch program is a multi-site initiative involving several high-enrolling ALS research centers, aimed at enhancing the understanding of biological effects of experimental products [4][5]